Next Article in Journal
A Phase II, Multicenter, Single-Arm Study of Mipsagargin (G-202) as a Second-Line Therapy Following Sorafenib for Adult Patients with Progressive Advanced Hepatocellular Carcinoma
Next Article in Special Issue
EV-Associated miRNAs from Peritoneal Lavage are a Source of Biomarkers in Endometrial Cancer
Previous Article in Journal
Breath Analysis: A Systematic Review of Volatile Organic Compounds (VOCs) in Diagnostic and Therapeutic Management of Pleural Mesothelioma
Previous Article in Special Issue
Targeting Palbociclib-Resistant Estrogen Receptor-Positive Breast Cancer Cells via Oncolytic Virotherapy
Open AccessReview

The Use of microRNAs in the Management of Endometrial Cancer: A Meta-Analysis

1
Cancer Biology and Therapeutics, Centre de Recherche Saint-Antoine (CRSA), Sorbonne University, INSERM UMR_S_938, 75020 Paris, France
2
Assistance Publique des Hôpitaux de Paris (AP-HP), Department of Gynecological and Breast Surgery and Oncology, Pitié-Salpêtrière University Hospital, 75013 Paris, France
3
Assistance Publique des Hôpitaux de Paris (AP-HP), Department of Obstetrics and Gynaecology, Tenon University Hospital, 75020 Paris, France
4
Centre National de la Recherche Scientifique (CNRS), 75012 Paris, France
5
Department of Gynecology, Groupe Hospitalier Diaconesses Croix Saint-Simon, 75020 Paris, France
6
INSERM U1016-Institut Cochin, UMR 8104, Team “From Gametes to Birth”, University Paris Descartes, 75014 Paris, France
7
Institut Universitaire de Cancérologie (IUC), 75020 Paris, France
*
Authors to whom correspondence should be addressed.
Cancers 2019, 11(6), 832; https://doi.org/10.3390/cancers11060832
Received: 16 May 2019 / Revised: 10 June 2019 / Accepted: 11 June 2019 / Published: 16 June 2019
(This article belongs to the Special Issue New Insights into Breast and Endometrial Cancer)
Introduction: Endometrial cancer (EC) is the most important gynecological cancer in terms of incidence. microRNAs (miRs), which are post-transcriptional regulators implicated in a variety of cellular functions including carcinogenesis, are particularly attractive candidates as biomarkers. Indeed, several studies have shown that the miR expression pattern appears to be associated with prognostic factors in EC. Our objective is to review the current knowledge of the role of miRs in carcinogenesis and tumor progression and their association with the prognosis of endometrial cancer. Materials and Method: We performed a literature search for miR expression in EC using MEDLINE, PubMed (the Internet portal of the National Library of Medicine) and The Cochrane Library, Cochrane databases “Cochrane Reviews” and “Clinical Trials” using the following keywords: microRNA, endometrial cancer, prognosis, diagnosis, lymph node, survival, plasma, FFPE (formalin-fixed, paraffin-embedded). The miRs were classified and presented according to their expression levels in cancer tissue in relation to different prognostic factors. Results: Data were collected from 74 original articles and 8 literature reviews which described the expression levels of 261 miRs in ECs, including 133 onco-miRs, 110 miR onco-suppressors, and 18 miRs with discordant functions. The review identified 30 articles studying the expression pattern of miR in neoplastic endometrial tissue compared to benign and/or hyperplastic tissues, 12 articles detailing the expression profile of miRs as a function of lymph node status, and 14 articles that detailed the expression pattern of miRs in endometrial tumor tissue according to overall survival or in the absence of recurrence. Conclusions: The findings presented here suggest that miR analysis merits a role as a prognostic factor in the management of patients with endometrial cancer. View Full-Text
Keywords: endometrial cancer; microRNA; survival; nodal involvement; prognostic endometrial cancer; microRNA; survival; nodal involvement; prognostic
MDPI and ACS Style

Delangle, R.; De Foucher, T.; Larsen, A.K.; Sabbah, M.; Azaïs, H.; Bendifallah, S.; Daraï, E.; Ballester, M.; Mehats, C.; Uzan, C.; Canlorbe, G. The Use of microRNAs in the Management of Endometrial Cancer: A Meta-Analysis. Cancers 2019, 11, 832. https://doi.org/10.3390/cancers11060832

AMA Style

Delangle R, De Foucher T, Larsen AK, Sabbah M, Azaïs H, Bendifallah S, Daraï E, Ballester M, Mehats C, Uzan C, Canlorbe G. The Use of microRNAs in the Management of Endometrial Cancer: A Meta-Analysis. Cancers. 2019; 11(6):832. https://doi.org/10.3390/cancers11060832

Chicago/Turabian Style

Delangle, Romain; De Foucher, Tiphaine; Larsen, Annette K.; Sabbah, Michèle; Azaïs, Henri; Bendifallah, Sofiane; Daraï, Emile; Ballester, Marcos; Mehats, Céline; Uzan, Catherine; Canlorbe, Geoffroy. 2019. "The Use of microRNAs in the Management of Endometrial Cancer: A Meta-Analysis" Cancers 11, no. 6: 832. https://doi.org/10.3390/cancers11060832

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop